[go: up one dir, main page]

WO1998013068A1 - Medicament prophylactique 'trisan' - Google Patents

Medicament prophylactique 'trisan' Download PDF

Info

Publication number
WO1998013068A1
WO1998013068A1 PCT/UA1996/000013 UA9600013W WO9813068A1 WO 1998013068 A1 WO1998013068 A1 WO 1998013068A1 UA 9600013 W UA9600013 W UA 9600013W WO 9813068 A1 WO9813068 A1 WO 9813068A1
Authority
WO
WIPO (PCT)
Prior art keywords
product
carrier
fact
culture
κachesτve
Prior art date
Application number
PCT/UA1996/000013
Other languages
English (en)
Russian (ru)
Inventor
Vladimir Borisovich Kuperman
Original Assignee
Vladimir Borisovich Kuperman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vladimir Borisovich Kuperman filed Critical Vladimir Borisovich Kuperman
Priority to PCT/UA1996/000013 priority Critical patent/WO1998013068A1/fr
Priority to AU18198/97A priority patent/AU1819897A/en
Publication of WO1998013068A1 publication Critical patent/WO1998013068A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention is subject to the field of medicine, in particular to the manufacture of a medical and pharmaceutical product, the benefit of 5 effective anti-inflammatory drugs.
  • the proposed product is intended for use for the treatment and treatment of diseases of the gastrointestinal tract - a small bowel disease associated with an erectile dysfunction of the whole gastric disease.
  • the closest known applicant is that the product is the product obtained from the patent of Russia ⁇ 2048123.1995.
  • the food product for food is provided by the carrier -
  • the number of microbial cells in the first product was 3.6 * 10.
  • the carrier in our product, the carrier
  • the main task of the invention was to treat the medical and therapeutic product by replacing the carrier and expanding the cross section.
  • -2- ⁇ rion of the used microorganisms to achieve expansion and strengthening of medical and therapeutic properties due to:
  • the indicated microorganisms (as a single species, and a large number of cases) is taken into account, because - intensification of the gastrointestinal tract in humans, biopharmaceuticals, treatments and other benign diseases with a disease;
  • P ⁇ s ⁇ avlennvya task ⁇ eshae ⁇ sya ⁇ em, ch ⁇ in lechebn ⁇ - ⁇ - ⁇ ila ⁇ iches ⁇ m ⁇ du ⁇ e, v ⁇ lgochagoschem n ⁇ si ⁇ el and su ⁇ y sub s ⁇ a ⁇ , s ⁇ de ⁇ zhaschy ⁇ e ⁇ a ⁇ a ⁇ ⁇ ul ⁇ u ⁇ y mi ⁇ ganizm ⁇ v, s ⁇ g- lasn ⁇ iz ⁇ b ⁇ e ⁇ enigo in ⁇ aches ⁇ ve n ⁇ si ⁇ elya ⁇ n s ⁇ de ⁇ zhi ⁇ la ⁇ - ⁇ e ⁇ men ⁇ i ⁇ vannye ⁇ as ⁇ i ⁇ elnye ⁇ m ⁇ nen ⁇ y, and ⁇ aches ⁇ ve mi ⁇ ganizm ⁇ v - ⁇ dnu or nes ⁇ l ⁇ ⁇ ul ⁇ u ⁇ m ⁇ l ⁇ chn ⁇ is- ly ⁇ ba ⁇ e ⁇ y and / or ⁇
  • lactobacilli both a and a bacilli
  • they have a very pronounced antagonism, a disease, prosthetics, and enteric infections. Therefore, the combination of lactobacilli with biopharmaceuticals in the treatment and treatment product should be more effective in protecting people from diabetes.
  • the microorganisms When the bacteria are removed, the microorganisms are dried, as it is, together with the substrate, - - they were cultivating. ⁇ We hereby declare the product to be free to eat, with or without the addition of sugar, in order to improve the pharmaceutical properties. The product "is written? Manufactured without the addition of sugar or with non-sugar sweeteners, it may be recommended that it suffers from diabetes mellitus.
  • Industrial equipment included in the treatment and treatment of the product "Risan” may be pre-treated - 6 - with hot or amylolytic and medicinal preparations for the conversion of proteins and arteries, which are related to non-mediocinous
  • the resulting low-molecular compounds serve as a substrate and stimulate growth for microorganisms. Particularly effective this product affects the accumulation in the substrate of bifidobacteria (Table ⁇ ).
  • the therapeutic product "Risan” is effective in the treatment and prevention of gastrointestinal diseases and related ones. the discrepancy is only for the claimed relationship between the carrier and the substrate, and the name (1-80): (99-20) .This is explained by the following service providers. In case of a decrease in the carrier’s share below the declared therapeutic effect of the product, there will be a unique occurrence of dry bacteria in the substrate, i.e. Only anti-traffic is ensured.
  • Sterilized youngsters were mixed with sterilized wheaten teeth.
  • the resulting mixture was added 50 g of dried extract (0 ⁇ 18-206-74) and 400 ml of leaven of microorganism in the ⁇ ⁇ ⁇ ⁇ - réelleêt ⁇ ⁇ ⁇ ⁇ .
  • the mixture was heated at a temperature of (38 ⁇ 0.5) ° ⁇ for 8 hours. After every 2 hours, the mixture was stirred for 20-30 seconds and adjusted to a medium, keeping it in the range of values 7.0-7.2, by adding 30% of Ya ⁇ solution.
  • Kund and regulyali ⁇ neighbors supporting it in the range of values 7.0-7.2, by adding 30 Ya ⁇ solution.
  • Examples 8-15 as a carrier, the product contains a SUSTAINABLE outlet, and in terms of microorganisms - a combination of two or two smaller cases.
  • EXAMPLES 16-23 as a carrier, the product contains barley, in the case of microorganisms it is one of the species of bacteria of the plant.
  • Examples 24-30 as a carrier, the product contains rye tubes, and as a combination of two or two types of products, the product contains a combination of two components.
  • Examples 31-36 as a carrier, the product contains a microcircuit, and in the case of microcircuits, there is only one or a few kinds of food.
  • Examples 37-45 as a carrier, the product is a part of the consumer, and in the case of microorganisms, it is small, but it is small
  • P ⁇ ime ⁇ y 46-60 in ⁇ aches ⁇ ve n ⁇ si ⁇ elya ⁇ du ⁇ s ⁇ de ⁇ zhi ⁇ ⁇ a ⁇ b ⁇ - me ⁇ iltsellyul ⁇ zu in ⁇ aches ⁇ ve mi ⁇ ganiem ⁇ v - ⁇ azlichn ⁇ e s ⁇ - che ⁇ anie m ⁇ l ⁇ chn ⁇ i ⁇ -yay ⁇ ba ⁇ e ⁇ y and ba ⁇ e ⁇ y, s ⁇ s ⁇ avlyayuschi ⁇ ⁇ leznuyu mi ⁇ l ⁇ u zhelud ⁇ chn ⁇ - ⁇ ishechn ⁇ g ⁇ ⁇ a ⁇ a chel ⁇ ve ⁇ a.
  • Example 61 on a carrier basis, the product contains wheat, fewer animals are declared, and on the other hand, there is a small difference.
  • the product may have been prepared for use in the manufacture of microbiological products.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte au domaine de la médecine et concerne plus particulièrement un produit médicamenteux prophylactique qui possède une activité anti-bactérienne. Ce produit, qui est destiné au traitement et à la prévention des troubles des voies gastro-intestinales chez l'homme, comprend un excipient ainsi qu'un substrat sec supportant une préparation d'une culture de micro-organismes. L'excipient représente de 1 à 80 parts en poids du produit, le reste se composant du substrat sec. On utilise en qualité d'excipient des composants végétaux lacto-fermentés tels que des fragments de céréales ou des préparations de cellulose, par exemple de la cellulose micro-cristalline ou de la carbométhylcellulose. On utilise en qualité de culture de micro-organismes une ou plusieurs cultures de bactéries d'acide lactique (du genre Lactobacillus et/ou Streptococcus), et/ou une ou plusieurs autres cultures utiles à la microflore des voies gastro-intestinales chez l'homme (du genre Bifidobacterium et/ou Escherichia coli et/ou Bacillus subtilis). Le produit décrit dans la présente invention possède une activité anti-microbienne élevée ainsi qu'un champ d'application étendu.
PCT/UA1996/000013 1996-09-26 1996-09-26 Medicament prophylactique 'trisan' WO1998013068A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/UA1996/000013 WO1998013068A1 (fr) 1996-09-26 1996-09-26 Medicament prophylactique 'trisan'
AU18198/97A AU1819897A (en) 1996-09-26 1996-09-26 Medicinal prophylactic "trisan"

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/UA1996/000013 WO1998013068A1 (fr) 1996-09-26 1996-09-26 Medicament prophylactique 'trisan'

Publications (1)

Publication Number Publication Date
WO1998013068A1 true WO1998013068A1 (fr) 1998-04-02

Family

ID=21688702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/UA1996/000013 WO1998013068A1 (fr) 1996-09-26 1996-09-26 Medicament prophylactique 'trisan'

Country Status (2)

Country Link
AU (1) AU1819897A (fr)
WO (1) WO1998013068A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007741A1 (fr) * 2000-07-25 2002-01-31 Borody Thomas J Therapie par recolonisation avec des probiotiques
GB2338244B (en) * 1998-01-20 2003-04-30 Shanghai Sine Pharmaceutical C A microbe composition, a method to prepare the same and uses thereof
US9649343B2 (en) 2011-03-09 2017-05-16 National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) Compositions and methods for transplantation of colon microbiota
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US9962413B2 (en) 2010-08-04 2018-05-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10195235B2 (en) 2016-08-03 2019-02-05 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11202808B2 (en) 2015-05-22 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11357801B2 (en) 2016-06-15 2022-06-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11542560B2 (en) 2012-05-25 2023-01-03 Board of Regents on Behalf of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US11819523B2 (en) 2016-07-01 2023-11-21 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1286212A1 (ru) * 1984-07-25 1987-01-30 2-й Московский государственный медицинский институт им.Н.И.Пирогова Способ лечени дисбактериоза кишечника
RU2035186C1 (ru) * 1992-07-09 1995-05-20 Семен Рафаилович Резник Профилактический биопрепарат споролакт
RU95110319A (ru) * 1995-06-19 1996-03-27 Акционерное общество открытого типа "Фармацевтическая фирма "КОНПО" Способ получения пробиотического препарата
RU2076722C1 (ru) * 1994-06-29 1997-04-10 Пермский фармацевтический институт Способ получения сухой биомассы лакто-, коли- или бифидобактерий

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2058681C1 (ru) * 1995-06-19 1996-04-20 Акционерное общество открытого типа Фармацевтическая фирма "КОНПО" Способ получения пробиотического препарата

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1286212A1 (ru) * 1984-07-25 1987-01-30 2-й Московский государственный медицинский институт им.Н.И.Пирогова Способ лечени дисбактериоза кишечника
RU2035186C1 (ru) * 1992-07-09 1995-05-20 Семен Рафаилович Резник Профилактический биопрепарат споролакт
RU2076722C1 (ru) * 1994-06-29 1997-04-10 Пермский фармацевтический институт Способ получения сухой биомассы лакто-, коли- или бифидобактерий
RU95110319A (ru) * 1995-06-19 1996-03-27 Акционерное общество открытого типа "Фармацевтическая фирма "КОНПО" Способ получения пробиотического препарата

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2338244B (en) * 1998-01-20 2003-04-30 Shanghai Sine Pharmaceutical C A microbe composition, a method to prepare the same and uses thereof
US9623056B2 (en) 2000-07-20 2017-04-18 Crestovo Llc Probiotic recolonisation therapy
US9572841B2 (en) 2000-07-25 2017-02-21 Crestovo Llc Probiotic recolonisation therapy
WO2002007741A1 (fr) * 2000-07-25 2002-01-31 Borody Thomas J Therapie par recolonisation avec des probiotiques
US9320763B2 (en) 2000-07-25 2016-04-26 Thomas Julius Borody Probiotic recolonisation therapy
US9408872B2 (en) 2000-07-25 2016-08-09 Crestovo Llc Probiotic recolonisation therapy
US9468658B2 (en) 2000-07-25 2016-10-18 Crestovo Llc Probiotic recolonisation therapy
US9572842B2 (en) 2000-07-25 2017-02-21 Crestovo Llc Probiotic recolonisation therapy
US10369175B2 (en) 2000-07-25 2019-08-06 Crestovo Holdings Llc Probiotic recolonisation therapy
US9610308B2 (en) 2000-07-25 2017-04-04 Crestovo Llc Probiotic recolonisation therapy
US9040036B2 (en) 2000-07-25 2015-05-26 Thomas Julius Borody Compositions for probiotic recolonisation therapy
US9050358B2 (en) 2000-07-25 2015-06-09 Thomas Julius Borody Compositions and methods for probiotic recolonization therapies
US9682108B2 (en) 2000-07-25 2017-06-20 Crestovo Llc Probiotic recolonisation therapy
US9737574B2 (en) 2000-07-25 2017-08-22 Crestovo Llc Probiotic recolonisation therapy
US9789140B2 (en) 2000-07-25 2017-10-17 Crestovo Holdings Llc Probiotic recolonisation therapy
US9867858B2 (en) 2000-07-25 2018-01-16 Crestovo Holdings Llc Probiotic recolonisation therapy
US10772919B2 (en) 2000-07-25 2020-09-15 Crestovo Holdings Llc Probiotic recolonisation therapy
US9901604B2 (en) 2000-07-25 2018-02-27 Crestovo Holdings Llc Probiotic recolonisation therapy
US9962414B2 (en) 2000-07-25 2018-05-08 Crestovo Holdings Llc Probiotic recolonisation therapy
US10849937B2 (en) 2010-08-04 2020-12-01 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11065284B2 (en) 2010-08-04 2021-07-20 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10022406B2 (en) 2010-08-04 2018-07-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890307B2 (en) 2010-08-04 2024-02-06 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10064899B1 (en) 2010-08-04 2018-09-04 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890308B2 (en) 2010-08-04 2024-02-06 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11850269B2 (en) 2010-08-04 2023-12-26 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11541080B2 (en) 2010-08-04 2023-01-03 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10278997B2 (en) 2010-08-04 2019-05-07 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11504403B2 (en) 2010-08-04 2022-11-22 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11491193B2 (en) 2010-08-04 2022-11-08 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10328107B2 (en) 2010-08-04 2019-06-25 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9962413B2 (en) 2010-08-04 2018-05-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10463702B2 (en) 2010-08-04 2019-11-05 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11207356B2 (en) 2010-08-04 2021-12-28 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10610551B2 (en) 2010-08-04 2020-04-07 Crestovo Holdings, Inc. Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10617724B2 (en) 2010-08-04 2020-04-14 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10675309B2 (en) 2010-08-04 2020-06-09 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11173183B2 (en) 2010-08-04 2021-11-16 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11129859B2 (en) 2010-08-04 2021-09-28 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11103541B2 (en) 2010-08-04 2021-08-31 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10857188B2 (en) 2010-08-04 2020-12-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10987385B2 (en) 2010-08-04 2021-04-27 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11801269B2 (en) 2011-03-09 2023-10-31 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10286011B2 (en) 2011-03-09 2019-05-14 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US12295974B2 (en) 2011-03-09 2025-05-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10028980B2 (en) 2011-03-09 2018-07-24 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US9649343B2 (en) 2011-03-09 2017-05-16 National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) Compositions and methods for transplantation of colon microbiota
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10251914B2 (en) 2011-03-09 2019-04-09 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10286012B2 (en) 2011-03-09 2019-05-14 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US11542560B2 (en) 2012-05-25 2023-01-03 Board of Regents on Behalf of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US12084727B2 (en) 2012-05-25 2024-09-10 Arizona Board Of Regents On Behalf Of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US10821138B2 (en) 2015-05-14 2020-11-03 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US12161678B2 (en) 2015-05-14 2024-12-10 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11123377B2 (en) 2015-05-14 2021-09-21 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11202808B2 (en) 2015-05-22 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11357801B2 (en) 2016-06-15 2022-06-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US12186349B2 (en) 2016-07-01 2025-01-07 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US11819523B2 (en) 2016-07-01 2023-11-21 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US10195235B2 (en) 2016-08-03 2019-02-05 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11071759B2 (en) 2016-08-03 2021-07-27 Finch Therapeutics Holdings Llc Methods for treating ulcerative colitis
US12390496B2 (en) 2016-08-03 2025-08-19 Finch Therapeutics Holdings Llc Methods for treating ulcerative colitis
US10561690B2 (en) 2016-08-03 2020-02-18 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11529375B2 (en) 2017-04-05 2022-12-20 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US12285447B2 (en) 2018-07-13 2025-04-29 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
AU1819897A (en) 1998-04-17

Similar Documents

Publication Publication Date Title
WO1998013068A1 (fr) Medicament prophylactique 'trisan'
RU2281326C2 (ru) ШТАММ БАКТЕРИЙ Escherichia coli, ПРЕДНАЗНАЧЕННЫЙ ДЛЯ НОРМАЛИЗАЦИИ ФИЗИОЛОГИЧЕСКОЙ АКТИВНОСТИ ЖЕЛУДОЧНО-КИШЕЧНОГО ТРАКТА, ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ, ПРЕДНАЗНАЧЕННАЯ ДЛЯ НОРМАЛИЗАЦИИ ФИЗИОЛОГИЧЕСКОЙ АКТИВНОСТИ ЖЕЛУДОЧНО-КИШЕЧНОГО ТРАКТА (ВАРИАНТЫ), И СПОСОБ ЕЕ ПОЛУЧЕНИЯ, СПОСОБ ВЫРАЩИВАНИЯ ШТАММА БАКТЕРИЙ Escherichia coli И ПИЩЕВОЙ ПРОДУКТ
KR100694820B1 (ko) 박테리아 균주 및 인간 및 수의학적 사용을 위한 생균활성 조성물
CN115074274B (zh) 含乳酸菌的组合物及其用途
AU2002221004A1 (en) Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
EP1867238B1 (fr) Composition d aliments pour betail comprenant un agent promoteur de la proliferation des bacteries bifidus et son utilisation
WO2007038466A2 (fr) Traitement d'un trouble bipolaire au moyen de compositions antifongiques
CN105685970A (zh) 一种全消化道改善的复合营养食品
RU2130316C1 (ru) Лечебно-профилактический биопрепарат "бактиспорин"
WO1994017671A1 (fr) Produit laitier aigre biologiquement actif 'acidolact-narineh' et son procede de production
CN101999556A (zh) 肉牛专用型动物营养素及其制备方法
EP3846831B1 (fr) Compositions d'associations de probiotiques
CN100413958C (zh) 具有抗肠道致病菌和抗氧化特性的双歧杆菌及其用途
WO2000070020A1 (fr) Souche de bacterie lactobacillus acidophilus n.v. ep 317/402 «narine» aaa utilisee dans la production de preparations ainsi que de produits dietetiques, therapeutiques et prophylactiques permettant de traiter la dysbacteriose et ses consequences
CN109700031A (zh) 用于肠道清洁、肠道排毒的营养组合物
CN112674203B (zh) 一种可降解赭曲霉毒素的微生态制剂及其制备方法
CN107467670A (zh) 一种益生菌制剂及其制备方法与应用
Savitha et al. Role of probiotic microbes exerting nutritional properties
KR20100037309A (ko) 유산균을 이용한 환형 건강보조식품의 제조방법
JPH11127815A (ja) ある種のオリゴ糖と微生物発酵茶の組合せによる健康維持
RU2377005C1 (ru) Способ лечения желудочно-кишечных болезней у телят
RU2246958C1 (ru) Биологически активный препарат для коррекции нарушений микрофлоры желудочно-кишечного тракта и повышения общей резистентности организма
JP2761815B2 (ja) 酪酸菌の液剤
WO2004005492A2 (fr) Composition probiotique a base d'une souche d'enterocoques pour moyens de traitement et de prevention et procede de fabrication correspondant
KR100483961B1 (ko) 유포자성 유산균을 함유한 수용성 인삼차 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU AZ BG BR BY CA CN CZ DE EE ES FI GB GE HU JP KG KP KR KZ LT LV MD MK MN MX PL RO RU SI SK TJ TM TR UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998515573

Format of ref document f/p: F